Stay updated on Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page.

Latest updates to the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page
- ChecktodayChange DetectedThe page shows a new revision tag (v3.6.3), indicating a recent update to the page's content or template. This update changes only metadata and does not modify the core study information presented.SummaryDifference0.0%

- Check8 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2. This appears to be an internal version update with no changes to study details or layout.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedEnrollment status now states No longer looking for participants, signaling that recruitment for the study is closed. New guidance and navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), and a formatting change to the Intervention/Treatment header alongside a version update to Revision: v3.6.0.SummaryDifference0.4%

- Check29 days agoChange DetectedThe footer revision tag was updated to v3.5.5, replacing v3.5.4. This indicates a minor backend/template update without impacting visible study details or actions.SummaryDifference0.0%

- Check51 days agoChange DetectedA new Revision: v3.5.4 was added to the page and the previous Revision: v3.5.3 was removed, indicating an update to the page's revision history.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page now reflects an updated ClinicalTrials.gov frontend revision (v3.5.3) instead of the previous one (v3.5.2), indicating a site release rather than a change to the trial’s content.SummaryDifference0.0%

Stay in the know with updates to Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page.